{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T15:40:39Z","timestamp":1783438839109,"version":"3.54.6"},"reference-count":66,"publisher":"Elsevier BV","issue":"44","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","award":["DC13-501A"],"award-info":[{"award-number":["DC13-501A"]}],"id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Iowa, College of Public Health"},{"name":"Department of Epidemiology"},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["631"],"award-info":[{"award-number":["631"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["39129"],"award-info":[{"award-number":["39129"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI25038"],"award-info":[{"award-number":["AI25038"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Carver College of Medicine"},{"name":"Holden Comprehensive Cancer Center"},{"name":"Iowa City Veteran\u2019s Administration Medical Center"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.vaccine.2016.09.016","type":"journal-article","created":{"date-parts":[[2016,9,21]],"date-time":"2016-09-21T21:30:17Z","timestamp":1474493417000},"page":"5225-5234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-9013","authenticated-orcid":false,"given":"Robert G.","family":"Schaut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara L.","family":"Grinnage-Pulley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Esch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela J.","family":"Toepp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm S.","family":"Duthie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall F.","family":"Howard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2016.09.016_b0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/CLEP.S44267","article-title":"Epidemiology of visceral leishmaniasis","volume":"6","author":"Ready","year":"2014","journal-title":"Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0010","doi-asserted-by":"crossref","first-page":"e35671","DOI":"10.1371\/journal.pone.0035671","article-title":"Leishmaniasis worldwide and global estimates of its incidence","volume":"7","author":"Alvar","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.09.016_b0015","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1111\/j.1469-0691.2011.03635.x","article-title":"Leishmaniasis impact and treatment access","volume":"17","author":"den Boer","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2016.09.016_b0020","doi-asserted-by":"crossref","first-page":"e1514","DOI":"10.1371\/journal.pntd.0001514","article-title":"Molecular mechanisms of drug resistance in natural Leishmania populations vary with genetic background","volume":"6","author":"Decuypere","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0025","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1128\/AAC.45.8.2185-2197.2001","article-title":"Clinical and experimental advances in treatment of visceral leishmaniasis","volume":"45","author":"Murray","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2016.09.016_b0030","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1586\/14787210.2014.916614","article-title":"Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?","volume":"12","author":"Vanaerschot","year":"2014","journal-title":"Expert Rev Anti-infective Theraphy"},{"key":"10.1016\/j.vaccine.2016.09.016_b0035","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.vaccine.2008.01.023","article-title":"Vaccines for leishmaniasis in the fore coming 25 years","volume":"26","author":"Palatnik-de-Sousa","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0040","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/0738-081X(96)00040-5","article-title":"Vaccine for prophylaxis and immunotherapy, Brazil","volume":"14","author":"Genaro","year":"1996","journal-title":"Clin Dermatol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0045","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fimmu.2012.00144","article-title":"Adjuvants for Leishmania vaccines: from models to clinical application","volume":"3","author":"Raman","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0050","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.4049\/jimmunol.1000238","article-title":"Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis","volume":"185","author":"Raman","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0055","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1016\/j.vaccine.2009.02.079","article-title":"Leishmania infantum sterol 24-c-methyltransferase formulated with MPL-SE induces cross-protection against L. major infection","volume":"27","author":"Goto","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0060","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1128\/CVI.05024-11","article-title":"KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis","volume":"18","author":"Goto","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0065","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.vaccine.2011.11.005","article-title":"The development and clinical evaluation of second-generation leishmaniasis vaccines","volume":"30","author":"Duthie","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0070","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1128\/IAI.00394-07","article-title":"Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells","volume":"75","author":"Coler","year":"2007","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2016.09.016_b0075","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.vaccine.2009.10.045","article-title":"Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis","volume":"28","author":"Velez","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0080","first-page":"1005","article-title":"Disseminated Leishmania infantum infection in two sibling foxhounds due to possible vertical transmission","volume":"49","author":"Gibson-Corley","year":"2008","journal-title":"Can Vet J"},{"key":"10.1016\/j.vaccine.2016.09.016_b0085","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/infdis\/jit401","article-title":"CD8 T cell exhaustion in human visceral leishmaniasis","volume":"209","author":"Gautam","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0090","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.vetpar.2015.07.005","article-title":"Immunological comparison of DNA vaccination using two delivery systems against canine leishmaniasis","volume":"212","author":"Shahbazi","year":"2015","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0095","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11259-015-9625-6","article-title":"Ability of immunodiagnostic tests to differentiate between dogs naturally infected with Leishmania infantum and Leishmune((R))-vaccinated dogs","volume":"39","author":"Ribeiro","year":"2015","journal-title":"Vet Res Commun"},{"key":"10.1016\/j.vaccine.2016.09.016_b0100","doi-asserted-by":"crossref","first-page":"e0003914","DOI":"10.1371\/journal.pntd.0003914","article-title":"Efficacy of recombinant canine distemper virus expressing leishmania antigen against leishmania challenge in dogs","volume":"9","author":"Miura","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0105","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s13071-015-0964-5","article-title":"A Leishmania-specific hypothetical protein expressed in both promastigote and amastigote stages of Leishmania infantum employed for the serodiagnosis of, and as a vaccine candidate against, visceral leishmaniasis","volume":"8","author":"Martins","year":"2015","journal-title":"Parasit Vect"},{"key":"10.1016\/j.vaccine.2016.09.016_b0110","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.vaccine.2014.11.039","article-title":"Vaccination using live attenuated Leishmania donovani centrin deleted parasites induces protection in dogs against Leishmania infantum","volume":"33","author":"Fiuza","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0115","first-page":"1","article-title":"An overview on Leishmania vaccines: a narrative review article","volume":"6","author":"Rezvan","year":"2015","journal-title":"Vet Res Forum: Int Quart J"},{"key":"10.1016\/j.vaccine.2016.09.016_b0120","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S1473-3099(10)70262-0","article-title":"Efficacy of RTS, S\/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5\u201317 months in Kenya and Tanzania: a randomised controlled trial","volume":"11","author":"Olotu","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0125","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS, S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0130","doi-asserted-by":"crossref","first-page":"5035","DOI":"10.1016\/j.vaccine.2015.08.033","article-title":"Prospects in Mycobacterium bovis Bacille Calmette et Guerin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?","volume":"33","author":"Moliva","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0135","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature01152","article-title":"CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity","volume":"420","author":"Belkaid","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2016.09.016_b0140","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.1502678","article-title":"Regulatory IgDhi B cells suppress T cell function via IL-10 and PD-L1 during progressive visceral leishmaniasis","author":"Schaut","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0145","doi-asserted-by":"crossref","first-page":"5542","DOI":"10.4049\/jimmunol.1301810","article-title":"Programmed death 1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte function","volume":"191","author":"Esch","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0150","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/CVI.00456-09","article-title":"Immunologic indicators of clinical progression during canine Leishmania infantum infection","volume":"17","author":"Boggiatto","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0155","doi-asserted-by":"crossref","first-page":"e1019","DOI":"10.1371\/journal.pntd.0001019","article-title":"Transplacental transmission of Leishmania infantum as a means for continued disease incidence in North America","volume":"5","author":"Boggiatto","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0160","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2460\/javma.2005.226.1316","article-title":"Autochthonous visceral leishmaniasis in dogs in North America","volume":"226","author":"Schantz","year":"2005","journal-title":"J Am Vet Med Assoc"},{"key":"10.1016\/j.vaccine.2016.09.016_b0165","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3201\/eid1203.050811","article-title":"Canine visceral leishmaniasis, United States and Canada, 2000\u20132003","volume":"12","author":"Duprey","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0170","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.vetimm.2015.11.008","article-title":"Immunologic progression of canine leishmaniosis following vertical transmission in United States dogs","volume":"169","author":"Vida","year":"2016","journal-title":"Vet Immunol Immunopathol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0175","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3201\/eid1203.050811","article-title":"Canine visceral leishmaniasis, United States and Canada, 2000\u20132003","volume":"12","author":"Duprey","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0180","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4269\/ajtmh.1983.32.480","article-title":"Immunofluorescent antibody test in American visceral leishmaniasis: sensitivity and specificity of different morphological forms of two Leishmania species","volume":"32","author":"Badar\u00f3","year":"1983","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2016.09.016_b0185","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1038\/cti.2015.6","article-title":"From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE","volume":"4","author":"Coler","year":"2015","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0190","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","article-title":"Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant","volume":"6","author":"Coler","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.09.016_b0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/ni758","article-title":"Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway","volume":"3","author":"Hemmi","year":"2002","journal-title":"Nat Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0200","doi-asserted-by":"crossref","first-page":"4100","DOI":"10.4049\/jimmunol.1502678","article-title":"Regulatory IgDhi B cells suppress T cell function via IL-10 and PD-L1 during progressive visceral leishmaniasis","volume":"196","author":"Schaut","year":"2016","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpath.2015.04.017","article-title":"Activation of autophagy and NLR family, pyrin domain containing 3 inflammasome during leishmania infantum-associated glomerulonephritis","author":"Esch","year":"2015","journal-title":"Am J Pathol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0210","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nrmicro2608","article-title":"Leishmaniasis: complexity at the host-pathogen interface","volume":"9","author":"Kaye","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0215","article-title":"The development and clinical evaluation of second-generation leishmaniasis vaccines","author":"Duthie","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0220","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.vaccine.2011.02.096","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis","volume":"29","author":"Chakravarty","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0225","doi-asserted-by":"crossref","first-page":"7427","DOI":"10.1016\/j.vaccine.2010.08.092","article-title":"A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis","volume":"28","author":"Llanos-Cuentas","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.04.067","article-title":"Strategic evaluation of vaccine candidate antigens for the prevention of visceral leishmaniasis","author":"Duthie","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0235","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.4049\/jimmunol.1003588","article-title":"IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis","volume":"186","author":"Ansari","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1297-9716-45-69","article-title":"The protective immune response produced in dogs after primary vaccination with the LiESP\/QA-21 vaccine (CaniLeish(R)) remains effective against an experimental challenge one year later","volume":"45","author":"Martin","year":"2014","journal-title":"Vet Res"},{"key":"10.1016\/j.vaccine.2016.09.016_b0245","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1084\/jem.20061141","article-title":"Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis","volume":"204","author":"Nylen","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2016.09.016_b0250","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/infdis\/jir461","article-title":"IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis","volume":"204","author":"Gautam","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0255","doi-asserted-by":"crossref","first-page":"e0003751","DOI":"10.1371\/journal.pntd.0003751","article-title":"Coadministration of the three antigenic leishmania infantum poly(A) binding proteins as a DNA vaccine induces protection against leishmania major infection in BALB\/c mice","volume":"9","author":"Soto","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0260","doi-asserted-by":"crossref","first-page":"e2174","DOI":"10.1371\/journal.pntd.0002174","article-title":"Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis","volume":"7","author":"Saljoughian","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0265","doi-asserted-by":"crossref","first-page":"e86073","DOI":"10.1371\/journal.pone.0086073","article-title":"Characterization of glycolytic enzymes\u2013rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis","volume":"9","author":"Gupta","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2016.09.016_b0270","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.parint.2014.07.010","article-title":"Short-term protection conferred by Leishvacin(R) against experimental Leishmania amazonensis infection in C57BL\/6 mice","volume":"63","author":"Carneiro","year":"2014","journal-title":"Parasitol Int"},{"key":"10.1016\/j.vaccine.2016.09.016_b0275","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.vaccine.2010.02.089","article-title":"Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE","volume":"28","author":"Trigo","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0280","doi-asserted-by":"crossref","first-page":"6176","DOI":"10.1016\/j.vaccine.2007.06.005","article-title":"Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine","volume":"25","author":"Santos","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0285","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0304-4017(94)90003-5","article-title":"Exploitation of parasite-derived antigen in therapeutic success against canine visceral leishmaniosis","volume":"54","author":"Neogy","year":"1994","journal-title":"Vet Parasitol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0290","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.vaccine.2009.09.071","article-title":"Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine visceral leishmaniasis","volume":"28","author":"Borja-Cabrera","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0295","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1016\/j.vaccine.2003.11.039","article-title":"Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine","volume":"22","author":"Borja-Cabrera","year":"2004","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2016.09.016_b0300","doi-asserted-by":"crossref","first-page":"e2729","DOI":"10.1371\/journal.pntd.0002729","article-title":"Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the immunotherapy of canine visceral leishmaniasis","volume":"8","author":"Ferreira","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2016.09.016_b0305","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.coi.2006.05.014","article-title":"Parasites and immunoregulatory T cells","volume":"18","author":"Belkaid","year":"2006","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0310","doi-asserted-by":"crossref","first-page":"e1003476","DOI":"10.1371\/journal.ppat.1003476","article-title":"T cell-derived IL-10 determines leishmaniasis disease outcome and is suppressed by a dendritic cell based vaccine","volume":"9","author":"Schwarz","year":"2013","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.vaccine.2016.09.016_b0315","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fimmu.2012.00251","article-title":"Immunobiology of visceral leishmaniasis","volume":"3","author":"Kumar","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2016.09.016_b0320","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.vaccine.2008.01.026","article-title":"Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis","volume":"26","author":"Miret","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0325","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1016\/j.vaccine.2007.05.010","article-title":"Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis","volume":"25","author":"Moreno","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2016.09.016_b0330","doi-asserted-by":"crossref","first-page":"5245","DOI":"10.1016\/j.vaccine.2005.07.001","article-title":"Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals","volume":"23","author":"Gradoni","year":"2005","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16308295?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X16308295?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T05:57:51Z","timestamp":1712383071000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X16308295"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":66,"journal-issue":{"issue":"44","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S0264410X16308295"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.09.016","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2016.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}